Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.32 |
| ▸ | CA2 | P00918 | 10/20 | 0.32 |
| ▸ | CA4 | P22748 | 10/20 | 0.32 |
| ▸ | CA9 | Q16790 | 10/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745908 | 1.00 | CA1 (0.32) | CA1CA2CA4CA9 | |
| SCHEMBL3493185 | 0.87 | CA1 (0.32) | CA1CA2CA4CA9 | |
| SCHEMBL20746064 | 0.85 | GPR119 (0.39) | — | |
| SCHEMBL30111425 | 0.85 | NR1H2 (0.41) | — | |
| SCHEMBL4283133 | 0.84 | KDM4E (0.37) | CA1CA2CA4CA9 | |
| SCHEMBL29102553 | 0.83 | CA1 (0.40) | CA1CA2CA4CA9 | |
| SCHEMBL15770735 | 0.83 | CA1 (0.40) | CA1CA2CA4CA9 | |
| SCHEMBL29102550 | 0.83 | CA1 (0.40) | CA1CA2CA4CA9 | |
| SCHEMBL22692079 | 0.82 | PDK1 (0.33) | — | |
| SCHEMBL22692078 | 0.82 | PDK1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| CN-114269735-B | Dihydro-or tetrahydroquinazoline compound, intermediate thereof, preparation method and application | 南京创济生物医药有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-26 | — | — | US | disclosed |
| EP-3844151-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-115803030-A | Compounds and methods for KRAS-targeted degradation | 阿维纳斯企业公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4132655-A1 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | Arvinas Operations, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2020101736-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10647715-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190270743-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-09-05 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-10647715-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | CA1 2054/4885CA2 3787/4885CA4 4292/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CA1 4282/4885CA2 3454/4885CA4 3576/4885 |
| US-20190270743-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.